How Lamzede Treats Alpha-Mannosidosis
Lamzede (velmanase alfa) is an enzyme replacement therapy (ERT) approved for non-central nervous system manifestations of alpha-mannosidosis, a lysosomal storage disorder caused by alpha-mannosidase deficiency.[1] It provides the missing enzyme, alpha-mannosidase, via intravenous infusion every two weeks, typically at 1 mg/kg body weight for patients aged 1 year and older.[1][2]
Mechanism of Action
Alpha-mannosidosis results from mutations in the MAN2B1 gene, leading to deficient lysosomal acid alpha-mannosidase. This causes mannose-rich oligosaccharides to accumulate in cells, triggering inflammation, tissue damage, skeletal abnormalities, hearing loss, and immune dysfunction.[1] Lamzede's recombinant human alpha-mannosidase breaks down these oligosaccharides in lysosomes, reducing substrate buildup and improving cellular function.[1][3] Uptake occurs via mannose-6-phosphate receptors on cell surfaces, targeting the enzyme to lysosomes.[2]
Clinical Evidence from Trials
In the Phase 3 MAN-01 trial (n=30 children aged 5-17), Lamzede reduced urinary oligosaccharide levels by 24-58% over 52 weeks versus minimal change in placebo.[1][4] It also improved fine motor function (e.g., 3-point grip test) and reduced fatigue. Glycoprotein clearance from leukocytes increased up to 4-fold.[3] Long-term data from extensions show sustained benefits in growth, pulmonary function, and adaptive behavior scores.[2][4] No trials address CNS symptoms, as the enzyme does not cross the blood-brain barrier effectively.[1]
Administration and Patient Considerations
Infusions start at 1 mg/kg over 4 hours, titrating to 2 hours; premedication with antihistamines or steroids manages infusion reactions (up to 88% of patients).[1][2] Common side effects include headache, fever, and urticaria; serious risks involve anaphylaxis or hypersensitivity.[1] Monitoring includes anti-drug antibodies (detected in 92% but rarely neutralizing) and IgG levels.[2] It's not curative but slows progression of peripheral symptoms like skeletal dysplasia and recurrent infections.[3]
Who Makes Lamzede and Availability
Chiesi Global Rare Diseases manufactures and markets Lamzede, approved by the FDA in February 2024 and EMA in 2020.[1][5] Pricing is not publicly detailed; access occurs via specialty pharmacies with prior authorization.[2]
Sources
[1]: Lamzede Prescribing Information (FDA)
[2]: Chiesi Lamzede HCP Site
[3]: European Medicines Agency Assessment Report
[4]: ClinicalTrials.gov MAN-01 Study (NCT01548469)
[5]: FDA Approval Announcement